Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06120491
Other study ID # D9723C00001
Secondary ID 2023-504214-30-0
Status Recruiting
Phase Phase 3
First received
Last updated
Start date November 21, 2023
Est. completion date April 30, 2031

Study information

Verified date April 2024
Source AstraZeneca
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Email information.center@astrazeneca.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.


Description:

Approximately 1800 adult participants with mCSPC will be assigned to one of two cohorts (550 HRRm and 1250 non-HRRm) and randomized in a 1:1 ratio to receive either Saruparib (AZD5305) with NHA or placebo with NHA. They will receive their assigned treatment and regular tumor evaluation scans until disease progression, or until treatment is stopped for another reason. All patients will be followed for survival until the end of the study. Independent data monitoring committee (DMC) composed of independent experts will be convened to confirm the safety and tolerability of Saruparib + physicians choice NHA.


Recruitment information / eligibility

Status Recruiting
Enrollment 1800
Est. completion date April 30, 2031
Est. primary completion date January 11, 2028
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 130 Years
Eligibility Inclusion Criteria: - Male = 18 years of age - Histologically documented prostate adenocarcinoma which is de novo or recurrent and castration-sensitive. Participants with pathologic features of small cell, neuroendocrine, sarcomatoid, spindle cell, or signet cell histology are not eligible. - Metastatic disease as documented by the investigator prior to randomisation, with clear evidence of = 1 bone lesion and/or = 1 soft tissue lesion that is suitable for repeated assessment with CT and/or MRI. - Participant is receiving ADT with a GnRH analogue or has undergone bilateral orchiectomy starting = 14 days and < 4 months prior to randomisation - ECOG performance status of 0 or 1 with no deterioration over the 2 weeks prior to randomisation. - Provision of FFPE tumour tissue sample and blood sample (for ctDNA) - Confirmed HRRm status by central tumour tissue and/or ctDNA test is required to determine cohort eligibility - Adequate organ and bone marrow function as described in study protocol - Participants must not father children or donate sperm from signing ICF, during the study intervention and for 6 months after the last dose of study intervention. - Participants must use a condom from signing ICF, during study intervention, and for 6 months after the last dose of study drug, with all sexual partners. Exclusion Criteria: - Participants with a history of MDS/AML or with features suggestive of MDS/AML - Participants with any known predisposition to bleeding - Any history of persisting (> 2 weeks) severe cytopenia - Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305 and/or the assigned NHA. - History of another primary malignancy, with exceptions - Persistent toxicities (CTCAE Grade = 2) caused by previous anticancer therapy. - Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention - Cardiac criteria, including history of arrythmia and cardiovascular disease - Any prior anticancer pharmacotherapy or surgery for metastatic prostate cancer, with exceptions: - Prior treatment within 14 days with blood product support or growth factor support. - Participants who are unevaluable for both bone and soft tissue progression

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Saruparib
Oral
Placebo
Oral
Abiraterone Acetate
Oral
Darolutamide
Oral
Enzalutamide
Oral

Locations

Country Name City State
Australia Research Site Chermside
Australia Research Site Darlinghurst
Australia Research Site Hyde Park
Australia Research Site Kurralta Park
Australia Research Site Melbourne
Australia Research Site Randwick
Australia Research Site South Brisbane
Austria Research Site Graz
Austria Research Site Innsbruck
Austria Research Site Krems an der Donau
Austria Research Site Linz
Austria Research Site Wien
Austria Research Site Wien
Belgium Research Site Charleroi
Belgium Research Site Gent
Belgium Research Site Kortrijk
Belgium Research Site Leuven
Brazil Research Site Curitiba
Brazil Research Site Pelotas
Brazil Research Site Porto Alegre
Brazil Research Site Porto Alegre
Brazil Research Site Rio de Janeiro
Brazil Research Site Salvador
Brazil Research Site Sao Luis
Brazil Research Site Sao Paulo
Brazil Research Site Sao Paulo
Brazil Research Site São Paulo
Canada Research Site Abbotsford British Columbia
Canada Research Site Calgary Alberta
Canada Research Site Calgary Alberta
Canada Research Site Chicoutimi Quebec
Canada Research Site Edmonton Alberta
Canada Research Site Greenfield Park Quebec
Canada Research Site Halifax Nova Scotia
Canada Research Site Kelowna British Columbia
Canada Research Site Kingston Ontario
Canada Research Site London Ontario
Canada Research Site Mississauga Ontario
Canada Research Site Montreal Quebec
Canada Research Site Montreal Quebec
Canada Research Site Montreal Quebec
Canada Research Site Newmarket Ontario
Canada Research Site Ottawa Ontario
Canada Research Site Quebec
Canada Research Site Saskatoon Saskatchewan
Canada Research Site Toronto Ontario
Canada Research Site Toronto Ontario
Canada Research Site Vancouver British Columbia
Canada Research Site Winnipeg Manitoba
Chile Research Site Concepcion
Chile Research Site La Serena
Chile Research Site Santiago
Chile Research Site Santiago
Chile Research Site Santiago
Chile Research Site Santiago
Chile Research Site Santiago
Chile Research Site Temuco
Chile Research Site Viña del Mar
China Research Site Beijing
China Research Site Beijing
China Research Site Beijing
China Research Site Beijing
China Research Site Beijing
China Research Site Changchun
China Research Site Changsha
China Research Site Chengdu
China Research Site Chongqing
China Research Site Chongqing
China Research Site Dongguan
China Research Site Guangzhou
China Research Site Guangzhou
China Research Site Guilin
China Research Site Hangzhou
China Research Site Hangzhou
China Research Site Harbin
China Research Site Jiaxing
China Research Site Jinan
China Research Site Lanzhou
China Research Site Nanchang
China Research Site Nanchang
China Research Site Nanjing
China Research Site Nantong
China Research Site Ningbo
China Research Site Shandong
China Research Site Shanghai
China Research Site Shanghai
China Research Site Shenyang
China Research Site Shenyang
China Research Site Suining
China Research Site Taiyuan
China Research Site Tianjin
China Research Site WeiFang
China Research Site Wenzhou
China Research Site Wuhan
China Research Site Xi'an
China Research Site Yantai
China Research Site Zhengzhou
Finland Research Site Helsinki
Finland Research Site Tampere
Finland Research Site Turku
France Research Site Angers
France Research Site Aurillac Cedex
France Research Site Bayonne
France Research Site Bordeaux Cedex
France Research Site Caen Cedex 5
France Research Site Clermont Ferrand
France Research Site Lyon
France Research Site Montpellier
France Research Site Nice
France Research Site Nimes
France Research Site Pierre Bénite
France Research Site Poitiers Cedex
France Research Site Quimper Cedex
France Research Site Rennes Cedex 9
France Research Site Strasbourg
France Research Site Tours
France Research Site Vandoeuvre les Nancy
Germany Research Site Bergisch Gladbach
Germany Research Site Berlin
Germany Research Site Bonn
Germany Research Site Braunschweig
Germany Research Site Dresden
Germany Research Site Duisburg
Germany Research Site Erlangen
Germany Research Site Frankfurt
Germany Research Site Frankfurt am Main
Germany Research Site Freiburg
Germany Research Site Göttingen
Germany Research Site Hamburg
Germany Research Site Heidelberg
Germany Research Site Herne
Germany Research Site Homburg
Germany Research Site Köln
Germany Research Site Magdeburg
Germany Research Site Mannheim
Germany Research Site Marburg
Germany Research Site Mettmann
Germany Research Site München
Germany Research Site Münster
Germany Research Site Nürtingen
Germany Research Site Oldenburg
Germany Research Site Regensburg
Germany Research Site Stuttgart
Germany Research Site Trier
Germany Research Site Tübingen
Germany Research Site Ulm
Hungary Research Site Budapest
Hungary Research Site Budapest
Hungary Research Site Budapest
Hungary Research Site Budapest
Hungary Research Site Debrecen
Hungary Research Site Gyor
Hungary Research Site Miskolc
Hungary Research Site Nyíregyháza
Hungary Research Site Szekszárd
India Research Site Bangalore
India Research Site Calicut
India Research Site Delhi
India Research Site Hyderabad
India Research Site JAipur
India Research Site Kolkata
India Research Site Kolkata
India Research Site Lucknow
India Research Site Mohali
India Research Site Nagpur
India Research Site New Delhi
India Research Site Pune
India Research Site Surat
India Research Site Vadodara
India Research Site Varanasi
Italy Research Site Bari
Italy Research Site Genoa
Italy Research Site Meldola
Italy Research Site Milano
Italy Research Site Milano
Italy Research Site Napoli
Italy Research Site Padova
Italy Research Site Rome
Italy Research Site Rozzano
Italy Research Site Terni
Italy Research Site Trento
Japan Research Site Chiba-shi
Japan Research Site Fukuoka
Japan Research Site Fukuoka-shi
Japan Research Site Hirakata-shi
Japan Research Site Hirosaki-shi
Japan Research Site Kanazawa-shi
Japan Research Site Kashihara-shi
Japan Research Site Kawagoe-shi
Japan Research Site Kisarazu-shi
Japan Research Site Kita-gun
Japan Research Site Kobe-shi
Japan Research Site Kumamoto-shi
Japan Research Site Maebashi-shi
Japan Research Site Nagano-shi
Japan Research Site Nagasaki-shi
Japan Research Site Nagoya
Japan Research Site Nagoya-shi
Japan Research Site Osaka-shi
Japan Research Site Osakasayama-shi
Japan Research Site Sagamihara-shi
Japan Research Site Sakura-shi
Japan Research Site Sapporo-shi
Japan Research Site Shiwa-gun
Japan Research Site Suita-shi
Japan Research Site Tsu-shi
Japan Research Site Yokohama-shi
Japan Research Site Yufu-shi
Korea, Republic of Research Site Daejeon
Korea, Republic of Research Site Seongnam-si
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Suwon
Malaysia Research Site George Town
Malaysia Research Site Johor Bahru
Malaysia Research Site Kota Kinabalu
Malaysia Research Site Kuala Lumpur
Malaysia Research Site Kuala Lumpur
Malaysia Research Site Kuching
Netherlands Research Site Amsterdam
Netherlands Research Site Hilversum
Netherlands Research Site Nijmegen
Peru Research Site Arequipa
Peru Research Site Lima
Peru Research Site Lima
Peru Research Site Lima
Peru Research Site Lima
Peru Research Site Lima
Poland Research Site Bydgoszcz
Poland Research Site Koszalin
Poland Research Site Poznan
Poland Research Site Rzeszów
Poland Research Site Szczecin
Poland Research Site Warszawa
Poland Research Site Wroclaw
Poland Research Site Zory
Spain Research Site Barcelona
Spain Research Site Córdoba
Spain Research Site L'Hospitalet de Llobregat
Spain Research Site Lugo
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Sabadell
Spain Research Site Valencia
Sweden Research Site Göteborg
Sweden Research Site Malmo
Sweden Research Site Solna
Sweden Research Site Stockholm
Taiwan Research Site Kaohsiung
Taiwan Research Site Kaohsiung city
Taiwan Research Site Taichung
Taiwan Research Site Taichung
Taiwan Research Site Taoyuan
Taiwan Research Site Yung Kang City
Thailand Research Site Bangkok
Thailand Research Site Bangkok
Thailand Research Site Bangkok
Thailand Research Site Chiang Mai
Thailand Research Site Khlong Luang
Thailand Research Site Songkla
Turkey Research Site Ankara
Turkey Research Site Ankara
Turkey Research Site Bornova-Izmir
Turkey Research Site Fatih-Istanbul
Turkey Research Site Istanbul
Turkey Research Site Karsiyaka
United Kingdom Research Site Aberdeen
United Kingdom Research Site Birmingham
United Kingdom Research Site Cambridge
United Kingdom Research Site Glasgow
United Kingdom Research Site Guildford
United Kingdom Research Site London
United Kingdom Research Site London
United Kingdom Research Site Manchester
United Kingdom Research Site Newcastle upon Tyne
United Kingdom Research Site Oxford
United Kingdom Research Site Plymouth
United Kingdom Research Site Preston
United Kingdom Research Site Swansea
United Kingdom Research Site Truro
United States Research Site Albany New York
United States Research Site Albuquerque New Mexico
United States Research Site Albuquerque New Mexico
United States Research Site Annapolis Maryland
United States Research Site Atlanta Georgia
United States Research Site Bakersfield California
United States Research Site Bala-Cynwyd Pennsylvania
United States Research Site Baltimore Maryland
United States Research Site Baltimore Maryland
United States Research Site Belleville New Jersey
United States Research Site Bethesda Maryland
United States Research Site Billings Montana
United States Research Site Bozeman Montana
United States Research Site Brick New Jersey
United States Research Site Bronx New York
United States Research Site Camden New Jersey
United States Research Site Chandler Arizona
United States Research Site Cincinnati Ohio
United States Research Site Cincinnati Ohio
United States Research Site Cleveland Ohio
United States Research Site Cleveland Ohio
United States Research Site Cleveland Ohio
United States Research Site Columbia Missouri
United States Research Site Columbus Ohio
United States Research Site Dallas Texas
United States Research Site Denton Texas
United States Research Site Des Moines Iowa
United States Research Site Durham North Carolina
United States Research Site East Brunswick New Jersey
United States Research Site Fairfax Virginia
United States Research Site Fayetteville North Carolina
United States Research Site Florence Oregon
United States Research Site Flower Mound Texas
United States Research Site Fort Wayne Indiana
United States Research Site Germantown Tennessee
United States Research Site Gilbert Arizona
United States Research Site Glenview Illinois
United States Research Site Golden Colorado
United States Research Site Grand Rapids Michigan
United States Research Site Grapevine Texas
United States Research Site Houston Texas
United States Research Site Houston Texas
United States Research Site Houston Texas
United States Research Site Indianapolis Indiana
United States Research Site Jacksonville Florida
United States Research Site Jacksonville Florida
United States Research Site Kansas City Kansas
United States Research Site Lake Barrington Illinois
United States Research Site Lakewood Colorado
United States Research Site Las Vegas Nevada
United States Research Site Las Vegas Nevada
United States Research Site Lexington Kentucky
United States Research Site Little Rock Arkansas
United States Research Site Los Angeles California
United States Research Site Los Angeles California
United States Research Site Louisville Kentucky
United States Research Site Montebello California
United States Research Site Myrtle Beach South Carolina
United States Research Site Nashville Tennessee
United States Research Site New Haven Connecticut
United States Research Site New Hyde Park New York
United States Research Site New York New York
United States Research Site New York New York
United States Research Site Newark Delaware
United States Research Site North Charleston South Carolina
United States Research Site Norwich Connecticut
United States Research Site Palm Bay Florida
United States Research Site Pasadena California
United States Research Site Philadelphia Pennsylvania
United States Research Site Phoenix Arizona
United States Research Site Pittsburgh Pennsylvania
United States Research Site Pittsburgh Pennsylvania
United States Research Site Plano Texas
United States Research Site Pomona California
United States Research Site Portland Oregon
United States Research Site Portland Oregon
United States Research Site Providence Rhode Island
United States Research Site Rio Rancho New Mexico
United States Research Site Rochester Minnesota
United States Research Site Sacramento California
United States Research Site Saint George Utah
United States Research Site Saint Petersburg Florida
United States Research Site Salt Lake City Utah
United States Research Site Salt Lake City Utah
United States Research Site San Antonio Texas
United States Research Site San Antonio Texas
United States Research Site San Diego California
United States Research Site San Francisco California
United States Research Site Santa Barbara California
United States Research Site Santa Monica California
United States Research Site Santa Rosa California
United States Research Site Scarborough Maine
United States Research Site Shirley New York
United States Research Site Shreveport Louisiana
United States Research Site Sioux Falls South Dakota
United States Research Site Spokane Washington
United States Research Site Spokane Valley Washington
United States Research Site Springdale Arkansas
United States Research Site Sugar Land Texas
United States Research Site Syracuse New York
United States Research Site Tacoma Washington
United States Research Site Tampa Florida
United States Research Site Towson Maryland
United States Research Site Troy Michigan
United States Research Site Tucson Arizona
United States Research Site Tyler Texas
United States Research Site Voorhees New Jersey
United States Research Site Wichita Kansas
United States Research Site Wichita Falls Texas
United States Research Site Winchester Virginia
United States Research Site York Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Belgium,  Brazil,  Canada,  Chile,  China,  Finland,  France,  Germany,  Hungary,  India,  Italy,  Japan,  Korea, Republic of,  Malaysia,  Netherlands,  Peru,  Poland,  Spain,  Sweden,  Taiwan,  Thailand,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of TEAEs (treatment emergent adverse events), SAEs (serious adverse events), and AEs (adverse events) leading to dose modifications up to approximately 90 months
Primary Radiographic Progression-Free Survival (rPFS) rPFS is defined as the time from randomisation to radiographic progression, as assessed by the investigator per RECIST 1.1 (soft tissue) and/or PCWG3 criteria (bone), or, death due to any cause. up to approximately 50 months
Secondary Overall Survival (OS) OS is defined as the time from randomisation until the date of death due to any cause. up to approximately 90 months
Secondary Second Progression-Free Survival (PFS2) Time from randomisation to PFS2 is defined as the time from randomisation to the earliest of progression (defined as radiographic progression, clinical progression, or PSA progression) after initiation of first subsequent treatment following the initial investigator-assessed progression or death. up to approximately 90 months
Secondary Time to First Subsequent Therapy or Death (TFST) TFST is defined as the time from randomisation to the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause. up to approximately 90 months
Secondary Symptomatic Skeletal Event-Free Survival (SSE-FS) SSE-FS is defined as the time from randomisation to the earliest of the following:
Use of radiation therapy to prevent or relieve skeletal symptoms.
Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral).
Occurrence of spinal cord compression.
Orthopaedic surgical intervention for bone metastasis.
Death due to any cause.
up to approximately 90 months
Secondary Time to the First Castration-Resistant Event (TTCR) TTCR is defined as the time from randomisation to the first castration resistant event (radiographic disease progression per RECIST 1.1 [soft tissue] and/or PCWG3 criteria [bone], PSA progression per PCWG3, or SSE, PSA progression per PCWG3, or SSE), whichever occurs first, with castrate levels of testosterone (below 50 ng/dL). up to approximately 90 months
Secondary Time to Pain Progression (TTPP) TTPP is defined as the time from randomisation to clinically meaningful pain progression based on a 2-point increase from baseline in the Brief Pain Inventory - Short Form (BPI-SF) Item 3 'worst pain in 24 hours' score and/or initiation of/increase in opioid analgesic use. up to approximately 90 months
Secondary Time To Deterioration in Urinary Symptoms (TTDUS) TTDUS is defined as the time from randomisation to deterioration in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Prostate Questionnaire (Urinary Symptoms) (QLQPR25 [US]) subscale scores. up to approximately 90 months
Secondary Time to Deterioration in Fatigue (TTDF) TTDF is defined as the time from randomisation to deterioration in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7A scores. up to approximately 90 months
Secondary Time to Deterioration in Physical Function (TTDPF) TTDPF is defined as the time from randomisation to deterioration in PROMIS Physical Function Short Form 8C scores. up to approximately 90 months
Secondary Health-related Quality of Life (HrQoL) Change from baseline in BPI-SF worst pain score, pain severity, and interference domain scores. up to approximately 90 months
Secondary BRCA and other HRR gene mutation status. at screening
Secondary Plasma concentrations of AZD5305 up to approximately 90 months
Secondary Samples will be used to develop complementary or companion diagnostics by analyzing their performance characteristics and calculate their consistency with clinical trial assays used for enrolment onto the study. Samples will be tested by a CDx to certify consistency with assays used in the study. up to approximately 90 months
Secondary PSA (prostate-specific antigen) undetectable rate at 6, 12 months proportion of participants with undetectable PSA (< 0.2 ng/mL) for those with PSA = 0.2 ng/mL at baseline up to approximately 90 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04497844 - A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Phase 3
Recruiting NCT04601441 - Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan Phase 4
Completed NCT04887506 - TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer Phase 3
Completed NCT05149131 - A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer
Active, not recruiting NCT04666129 - Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer Phase 1